Solid Tumours

  • T. J. Priestman


The results of treatment in lung cancer depend on three main factors: the histological type of the tumour, the stage of disease and the general condition of the patient. From a therapeutic viewpoint the various histological types of lung cancer can be divided into two main groups: small cell carcinomas (also called oat-cell carcinomas), which make up about 20 per cent of cases, and non-small cell cancers, which form the remaining 80 per cent of bronchogenic carcinomas, including squamous cell carcinomas, adenocarcinomas and large cell cancers. The management of these two forms of lung cancer differs considerably.


Advanced Breast Cancer Cytotoxic Therapy Luteinising Hormone Release Hormone Hydatidiform Mole Anal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Lung cancer. Bunn P (editor) (1988) Seminars in Oncology, 15: 197–315Google Scholar
  2. National lung cancer conference. Various authors (1987) British Journal of Cancer, 56: 881–900CrossRefGoogle Scholar
  3. Lung cancer: when to give chemotherapy. Anonymous (1988) Drug and Therapeutics Bulletin, 26: 29–30Google Scholar
  4. Treatment of non-small cell lung cancer. Mulshine JL, Glatstein E, Ruckdeschel JC (1986) Journal of Clinical Oncology, 4: 1704–1715PubMedGoogle Scholar
  5. Advanced non-small cell lung cancer: to treat or not to treat. Hansen HH (1987) Journal of Clinical Oncology, 5: 1711–1712PubMedGoogle Scholar
  6. The medical management of breast cancer. Williams CJ, Buchanan RB. Castle House Publications, Tunbridge Wells, 1987Google Scholar
  7. Adjuvant therapy for breast cancer. Henderson CI (1988) New England Journal of Medicine, 318: 443–444PubMedCrossRefGoogle Scholar
  8. Adjuvant tamoxifen in early breast cancer. Anonymous (1987) Lancet, 2: 191–192Google Scholar
  9. Adjuvant tamoxifen for early breast cancer. Smith I (1988) British Journal of Cancer, 57: 527–528PubMedCrossRefGoogle Scholar
  10. Gastrointestinal oncology. Fielding JWL, Priestman TJ. Castle House Publications, Tunbridge Wells, 1986Google Scholar
  11. Surgical adjuvant treatment of large bowel cancer. Moertel CG (1988) Journal of Clinical Oncology, 6: 934–936PubMedGoogle Scholar
  12. Perspectives on treatment of large bowel cancer. Wittes RE (1988) Journal of the National Cancer Institute, 80: 5–7PubMedCrossRefGoogle Scholar
  13. Management of metastatic cancer of the prostate. Williams G (1988) Prescribers’ Journal, 28: 43–48Google Scholar
  14. Prostate cancer. Chisholm GD (1986) Cancer Topics, 6; 10–11Google Scholar
  15. Management of metastatic prostatic carcinoma. Anonymous (1986) Drug & Therapeutics Bulletin, 24: 85–88Google Scholar
  16. Renal-cell carcinoma. Harris DT, Maguire HC (editors) (1983) Seminars in Oncology, 10: 365–440PubMedGoogle Scholar
  17. Chemotherapy of disseminated germ cell tumors. Einhorn LH (1987) Cancer, 60: 570–573PubMedCrossRefGoogle Scholar
  18. Testis cancer. Oliver RTD (1984) British Journal of Hospital Medicine, 18: 23–35Google Scholar
  19. Clinical stage I carcinoma of the testis: a review. Fung CY, Garnick MB (1988) Journal of Clinical Oncology, 6: 734–750PubMedGoogle Scholar
  20. The management of advanced testicular teratoma. Peckham MJ, Harwich A, Easton DF, Hendry WF (1988) British Journal of Urology, 62: 63–68PubMedCrossRefGoogle Scholar
  21. Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasion bladder cancer. Raghaven D (1988) British Journal of Urology, 61: 1–8CrossRefGoogle Scholar
  22. Chemotherapy of urothelial tract tumors. Yagoda A (1987) Cancer, 60: 574–585PubMedCrossRefGoogle Scholar
  23. Common epithelial cancers of the ovary. Richardson GS, Scully RE, Nikrui N, Nelson JH (1985). New England Journal of Medicine, 312: 415–423 & 474–482PubMedCrossRefGoogle Scholar
  24. Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data. Dembo AJ (1986) Journal of Clinical Oncology, 4: 1573–1576PubMedGoogle Scholar
  25. Treating ovarian cancer. Burslem RW, Wilkinson PM (1986) British Medical Journal, 293: 972–973PubMedCrossRefGoogle Scholar
  26. Chemotherapy for advanced or recurrent gynecologic cancer. Thigpen T, Vance R, Lambuth B etal (1987) Cancer, 60: 2104–2116PubMedCrossRefGoogle Scholar
  27. Chemotherapy of gynecologic cancer (1984) Deppe G (editor) Alan R Liss, New York.Google Scholar
  28. Developments in chemotherapy for medium and high-risk patients with gestational trophoblastic tumours (1979-1984). Newlands ES, Bagshawe KD, Begent RHJ, et al. (1986) British Journal of Obstetrics and Gynaecology, 93: 63–69PubMedCrossRefGoogle Scholar
  29. Head and neck cancer. Brady LW (editor) (1988) Seminars in Oncology, 15: 1–99Google Scholar
  30. Why has so much chemotherapy done so little in head and neck cancer? Taylor SG (1987) Journal of Clinical Oncology, 5: 1–3PubMedGoogle Scholar
  31. Brain tumours. Shapiro WR (editor) (1986) Seminars in Oncology, 13: 1–129Google Scholar
  32. An overview of published results of randomised studies of nitrosoureas in primary high grade malignant glioma. Stenning SP, Freedman LS, Bleehen NM (1987) British Journal of Cancer, 56: 89–90PubMedCrossRefGoogle Scholar
  33. Malignant melanoma of the skin. Anonymous (1988). Drug & Therapeutics Bulletin, 26: 73–75Google Scholar
  34. Osteosarcoma: fifteen years later. Goorin AM, Abelson HT, Frei E (1986) New England Journal of Medicine, 313: 1637–1642CrossRefGoogle Scholar
  35. Management of primary malignant bone tumours. Souhami RL (1987) Hospital Update, 13: 997–1009Google Scholar
  36. Soft tissue sarcomas. Steward WP, Bramwell VHC (1986) Cancer Topics, 5: 138–140Google Scholar
  37. The treatment of soft tissue sarcoma with focus on chemotherapy: a review. Pinedo HM, Verwij J (1986) Radiotherapy and Oncology, 5: 193–205PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • T. J. Priestman
    • 1
  1. 1.Queen Elizabeth HospitalEdgbaston, BirminghamUK

Personalised recommendations